Teladoc Health, Inc. (NYSE:TDOC) Shares Purchased by Banco Santander S.A.

Banco Santander S.A. raised its stake in shares of Teladoc Health, Inc. (NYSE:TDOCGet Rating) by 2,837.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 104,559 shares of the health services provider’s stock after acquiring an additional 101,000 shares during the period. Banco Santander S.A. owned approximately 0.06% of Teladoc Health worth $7,542,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Lincoln National Corp lifted its position in shares of Teladoc Health by 42.7% during the 1st quarter. Lincoln National Corp now owns 3,955 shares of the health services provider’s stock worth $285,000 after buying an additional 1,184 shares during the last quarter. M&T Bank Corp lifted its position in shares of Teladoc Health by 9.1% during the 1st quarter. M&T Bank Corp now owns 6,734 shares of the health services provider’s stock worth $485,000 after buying an additional 561 shares during the last quarter. RiverPark Advisors LLC purchased a new stake in shares of Teladoc Health during the 1st quarter worth approximately $6,093,000. Riverpark Capital Management LLC purchased a new stake in shares of Teladoc Health during the 1st quarter worth approximately $3,810,000. Finally, Los Angeles Capital Management LLC increased its holdings in shares of Teladoc Health by 431.5% in the 1st quarter. Los Angeles Capital Management LLC now owns 14,397 shares of the health services provider’s stock valued at $1,038,000 after acquiring an additional 11,688 shares during the period. 87.17% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Teladoc Health

In other Teladoc Health news, CFO Mala Murthy sold 4,053 shares of the stock in a transaction dated Monday, June 27th. The stock was sold at an average price of $37.32, for a total value of $151,257.96. Following the completion of the sale, the chief financial officer now directly owns 27,295 shares in the company, valued at $1,018,649.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Teladoc Health news, CFO Mala Murthy sold 4,053 shares of the stock in a transaction dated Monday, June 27th. The stock was sold at an average price of $37.32, for a total value of $151,257.96. Following the completion of the sale, the chief financial officer now directly owns 27,295 shares in the company, valued at $1,018,649.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Daniel Trencher sold 1,000 shares of the stock in a transaction dated Monday, July 18th. The stock was sold at an average price of $41.12, for a total value of $41,120.00. Following the completion of the sale, the senior vice president now owns 27,408 shares of the company’s stock, valued at $1,127,016.96. The disclosure for this sale can be found here. Over the last quarter, insiders sold 6,053 shares of company stock worth $221,498. 1.55% of the stock is owned by insiders.

Teladoc Health Stock Performance

TDOC stock opened at $37.48 on Friday. The business has a fifty day moving average of $36.47 and a 200-day moving average of $51.88. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.71 and a current ratio of 3.94. Teladoc Health, Inc. has a twelve month low of $27.38 and a twelve month high of $156.82.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on TDOC shares. Needham & Company LLC cut shares of Teladoc Health from a “buy” rating to a “hold” rating in a research note on Thursday, July 28th. Craig Hallum dropped their price objective on shares of Teladoc Health from $67.00 to $30.00 in a research note on Thursday, April 28th. JPMorgan Chase & Co. downgraded shares of Teladoc Health from an “overweight” rating to a “neutral” rating in a research report on Thursday, April 28th. Cowen downgraded shares of Teladoc Health from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $58.00 to $34.00 in a research report on Tuesday. Finally, Robert W. Baird lowered their price objective on shares of Teladoc Health from $72.00 to $64.00 in a research report on Wednesday, April 27th. One research analyst has rated the stock with a sell rating, twenty-three have issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, Teladoc Health presently has a consensus rating of “Hold” and a consensus price target of $71.03.

Teladoc Health Company Profile

(Get Rating)

Teladoc Health, Inc provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions.

Further Reading

Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health, Inc. (NYSE:TDOCGet Rating).

Institutional Ownership by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.